The Challenge of Globalization in Pharmaceutical Law - Is an International Harmonization of Drug Approval Procedures Modeled after the European System Worth Considering?

Food and Drug Law Journal, Vol. 63, pp. 623-645, 2008

Posted: 16 Oct 2008 Last revised: 9 Feb 2014

See all articles by Kai P. Purnhagen

Kai P. Purnhagen

University of Bayreuth; Erasmus University of Rotterdam - Rotterdam Institute of Law and Economics

Date Written: August 15, 2008

Abstract

Pharmaceutical Companies are highly globalized. This widening of drug markets leads to an erosion of the national government's legislative powers. With trials and marketing of compounds and pharmaceuticals carried out in different countries, ensuring safety and effectiveness of drugs becomes increasingly problematic.

Thus, international pharmaceutical approval harmonization as well as drug monitoring, belongs paramount. One way of solving this problem might be to model an international pharmaceutical authorization system on the European Decentralized Procedure with involvement of the International Conferences of Harmonisation. That's the focus of this article.

Keywords: Globalization, Drug, Pharmaceutical, Europe, Law, Approval

JEL Classification: K13, K23, K32, K33

Suggested Citation

Purnhagen, Kai Peter, The Challenge of Globalization in Pharmaceutical Law - Is an International Harmonization of Drug Approval Procedures Modeled after the European System Worth Considering? (August 15, 2008). Food and Drug Law Journal, Vol. 63, pp. 623-645, 2008, Available at SSRN: https://ssrn.com/abstract=1285049

Kai Peter Purnhagen (Contact Author)

University of Bayreuth ( email )

Universitatsstr 30
Bayreuth, D-95447
Germany

Erasmus University of Rotterdam - Rotterdam Institute of Law and Economics ( email )

Burgemeester Oudlaan 50
PO box 1738
Rotterdam, 3000 DR
Netherlands

Do you have negative results from your research you’d like to share?

Paper statistics

Abstract Views
848
PlumX Metrics